Tryptamine fingerprints in the classification of 5-hydroxytryptamine receptors

  • G. R. Martin
  • P. Leff
  • S. J. Maclennan
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)


In a series of recent studies [1–4] we have investigated the utility of tryptamines in the classification of 5-hydroxytryptamine (5-HT) receptors. These studies have shown that in situations where conventional antagonists are unable to provide reliable quantitative information, ‘fingerprints’ comprising tryptamine affinity and relative efficacy estimates can improve the rigour with which 5-HT receptors are classified. A particular advantage of this approach is that it enables receptors to be identified positively. This is in contrast to the scheme proposed by Bradley et al. [5] in which, for example 5-HT1-like receptors are defined by a high agonist potency (≥5-HT) of 5-carboxamidotryptamine (5-CT), susceptibility to blockade by the nonselective antagonist methiothepin and a resistance to blockade by ketanserin and MDL 72222. In our view, application of such exclusion criteria establishes what the receptor is not rather than what it is.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Leff P, Martin GR, Morse JM (1986): The classification of peripheral 5-HT2-like receptors using tryptamine agonist and antagonist analogues. Br J Pharmacol 89: 493–499.PubMedCrossRefGoogle Scholar
  2. 2.
    Leff P, Martin GR, Morse JM (1987): Differential classification of vascular smooth muscle and endothelial cell 5-HT receptors by use of tryptamine analogues. Br J Pharmacol 91: 321–331.PubMedCrossRefGoogle Scholar
  3. 3.
    Martin GR, Leff P, Cambridge D, Barrett VJ (1987): Comparative analysis of two types of 5-hydroxytryptamine receptor mediating vasorelaxation: differential classification using tryptamines. Naunyn-Schmiedeberg’s Arch Pharmacol 336: 365–375.CrossRefGoogle Scholar
  4. 4.
    Martin GR, Leff P, MacLennan SJ, Dougall I (1988): Three types of 5-HT1-like receptor recognised by tryptamine affinity and efficacy “fingerprints”. Br J Pharmacol 95: 626P.Google Scholar
  5. 5.
    Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986): Proposals for the classification and nomenclature of functional receptors of 5-hydroxytryptamine. Neuropharmacol 25: 563–576.CrossRefGoogle Scholar
  6. 6.
    Leff P, Martin GR (1986): Peripheral 5-HT2-like receptors. Can they be classified with the available antagonists? Br J Pharmacol 88: 585–593.PubMedCrossRefGoogle Scholar
  7. 7.
    Furchgott RF (1966): The use of β-haloalkylamines in the differentiation of receptors and determination of dissociation constants of receptor-agonist complexes. Adv Drug Res 3: 21–55.Google Scholar
  8. 8.
    Feniuk W, Humphrey PPA, Perren MJ, Watts AD (1985): A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists. Br J Pharmacol 86:697–704.PubMedCrossRefGoogle Scholar
  9. 9.
    Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW, Coates IH, Butina D (1988): GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 94: 1123–1132.PubMedCrossRefGoogle Scholar
  10. 10.
    Stephenson RP (1975): Interactions of agonists and antagonists with their receptors, pp. 15–28 in: Warcel M, Vassort G (eds), Les colloques de I’institute de la santé et de la recherche medicale. Smooth Muscle Pharmacology and Physiology. Vol. 50.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • G. R. Martin
  • P. Leff
  • S. J. Maclennan

There are no affiliations available

Personalised recommendations